Search
Filter Results
Displaying 431–440 of 958 results
-
Jan 28, 2021
The company plans to enroll additional patients as young as four years old
-
Jan 26, 2021
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
-
Jan 26, 2021
In honor of Rare Disease Day, this February 28th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Jan 25, 2021
Jenny was diagnosed with retinitis pigmentosa (RP), just like her mom, at the age of 34. In her own words, Jenny shares her experience with being diagnosed with RP and her journey to accepting it with hopefulness.
-
Jan 13, 2021
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Company also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
Jan 7, 2021
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
In a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
The Foundation’s Strategic Council is a group of young professionals with an affinity to the Fighting Blindness mission and represent the next generation of Foundation leaders.
-
Dec 21, 2020
At seven years old, Hannah had never seen a lightning bug in the summer or a star in the sky. But after her treatment with LUXTURNA, Hannah can now play outside at night with her brothers and has a new bright future in store.
-
A friendly year end reminder to make sure you are aware of a popular end-of-year giving opportunity. In 2020, organizations like the Foundation Fighting Blindness have seen a huge uptick in gifts made through appreciated stock/securities. This is a great way to avoid capital gains taxes AND support a mission that’s important to you.
-
Dec 16, 2020
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.